Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06436651
Other study ID # E.795978
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 13, 2023
Est. completion date September 2024

Study information

Verified date June 2024
Source Kocaeli University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this clinical study is to evaluate the effectiveness of the digital storytelling method in symptom management in children diagnosed with oncology. It will also provide information about children's experiences with Digital Storytelling and the use of the method. The main questions it aims to answer are: - Is there a difference between the anxiety scores of children who applied the Digital Storytelling Method and those who did not? - Is there a difference between the fatigue scores of children who applied the Digital Storytelling Method and those who did not? - Is there a difference between the nausea scores of children who applied the Digital Storytelling Method and those who did not? - Is there a difference between the pain scores of children who applied and did not apply the Digital Storytelling Method? Participants: Complete the first stage data forms. Visit the clinic every 7-15 days for the digital storytelling process, which consists of 4 stages. After the storytelling process is completed, have a process evaluation meeting with the researcher.


Description:

Participants; Enterprise Group, 1. Interview (Week 1); Meeting the child, conducting a qualitative interview for needs analysis and introducing the forms 2. Interview (Week 2); Finding a digital story topic 3. Interview (Week 3); Writing a story on the specified topic 4. Interview (Week 4); Converting the story into digital form 5. Interview (Week 5); Showing the created story 6. Interview (Week 6); Conducting a qualitative interview regarding the digital storytelling process. Each meeting will be held in 1-week periods. Primary outcome tools will be applied as pretest and posttest once in the 1st and 6th interviews, and twice in the other interviews. Control Group; 1. Interview (Week 1); Meeting the child, introducing and applying the forms 2. Interview (Week 6); Conducting a qualitative interview regarding the digital storytelling process. Showing the videos prepared by the children in the initiative group. Application of primary outcome tools.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date September 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 7 Years to 18 Years
Eligibility Inclusion Criteria: - 7-18 years old, - Having received at least 1 cure of treatment, - Completed the induction phase and is in the consolidation phase, - Children who and their parents agree to participate in the study. Exclusion Criteria: - who cannot speak Turkish, - Having a secondary chronic disease - Having a second disease that will affect the cognitive process, - Children/adolescents who cannot complete the 4 stages of the digital storytelling process. - Children/adolescents who cannot complete the 4 stages of the digital storytelling process. - Children/adolescents who take a break of more than 3 weeks between storytelling processes.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Digital Storytelling
4 stages of digital storytelling will be implemented.

Locations

Country Name City State
Turkey Kocaeli University Kocaeli Izmit

Sponsors (2)

Lead Sponsor Collaborator
Kocaeli University Gazi University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary State-Trait Anxiety Inventory for Children It will be used to evaluate children's state anxiety. It will be used in the 1st and 6th interviews with the child (1st week-6th week).
Primary Visual Analogue Scale for Fatigue It is a single-item scale used to determine the intensity of fatigue in patients. The patient is asked to score his or her fatigue on a scale of 0-10. 0 means no fatigue, while 10 is considered a lot of fatigue. It will be applied in all interviews with the child (6 interviews), before and after the interview. It will be applied 12 times in 6 weeks.
Primary The Baxter Retching Faces Scale The scale is applied to children/adolescents in the 7-18 age group. There are a total of six items in the scale, ranging from no force to vomiting, and six facial expressions indicating each item. While the scale can be used by asking the child to choose the face that best suits him/her, the cartoon can also be shown and evaluated through observation. The average application time of the scale is 2 minutes and scores are given between 0-10. Using 0 as 'no nausea' and 10 as 'vomiting' It will be applied in all interviews with the child (6 interviews), before and after the interview. It will be applied 12 times in 6 weeks.
Primary Wong-Baker FACES pain rating scale (WB-FACES) This scale is used to diagnose pain in children aged 3-18. This scale has six faces representing increasing pain intensity from zero to five from left to right. The far left face has a smiling expression, indicating a pain-free state, while the far right face has a crying expression, corresponding to the most severe pain. Six facial expressions are scored from left to right on a scale of 0 to 10 points (0 points = very happy/no pain, 10 points = most severe pain). As the score from the scale increases, pain tolerance decreases, and as the score decreases, tolerance increases. The child is told to choose the face that best expresses his or her emotions. It will be applied in all interviews with the child (6 interviews), before and after the interview. It will be applied 12 times in 6 weeks.
Secondary SSPedi: Symptom Screening Scale in Pediatric Patients The screening tool includes 15 symptoms that evaluate the symptoms children have experienced in the last two days. Each symptom is evaluated with a 5-point Likert-type scoring system, and the score range varies between 0-60. Higher scores indicate that the number of symptoms and the discomfort they cause increase. It will be used in the 1st and 6th interviews with the child (1st week-6th week).
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients